Periodic Reporting for period 1 - N-IF (The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies)
Période du rapport: 2017-12-01 au 2018-05-31
Fibrosis, or scar tissue within an organ, is a global problem and currently there are no efficient therapies aimed against fibrotic diseases despite their high prevalence among the world population and their huge impact on human health.
Pharma companies are struggling to develop anti-fibrotic drugs due to a lack of good and reliable preclinical models that better resemble human fibrotic disease conditions.
The N-IF mouse, developed by InfiCure Bio, is the first animal model that exhibits the same course of fibrotic disease progression as in humans, is 100% reproducible and spontaneously develops fibrosis. The objectives of the Phase 1 N-IF project were to conduct a feasibility report and prepare for further validation studies of the mouse model in order to establish the pathology of non-alcoholic steatohepatitis (NASH), renal and pulmonary fibrosis enlarging the pipeline models for fibrotic diseases.
Pharma companies are struggling to develop anti-fibrotic drugs due to a lack of good and reliable preclinical models that better resemble human fibrotic disease conditions.
The N-IF mouse, developed by InfiCure Bio, is the first animal model that exhibits the same course of fibrotic disease progression as in humans, is 100% reproducible and spontaneously develops fibrosis. The objectives of the Phase 1 N-IF project were to conduct a feasibility report and prepare for further validation studies of the mouse model in order to establish the pathology of non-alcoholic steatohepatitis (NASH), renal and pulmonary fibrosis enlarging the pipeline models for fibrotic diseases.
The feasibility study was performed using the Strategic Business Planning Methodology which resulted in an overall business development strategy for the company. The data collected provided a valuable understanding of the current trends and opportunities on the fibrosis market, targeted users, competitors and potential partnerships. The assessment also resulted in a work plan for carrying out validation studies that will provide evidence that usage of the products will lead to a faster and more efficient development of drugs against fibrotic disease. The feasibility study has confirmed that there is a clear business opportunity to exploit on the global fibrosis market and to deliver new experimental models for efficacy testing of anti- fibrotic and anti-inflammatory therapeutics.
The feasibility study has further confirmed the innovative character of InfiCure Bio’s products. Their unique features such spontaneous development of fibrosis and 100% reproducibility will allow to shorten test protocols by 4-8 weeks, increase robustness of tests and minimize the number of experimental animals needed. Reductions in experiment time and in mice numbers directly translate into a 25 - 50% decrease in the overall costs of preclinical testing of anti-fibrotic drugs. InfiCure Bio will deliver a novel tool for the development of efficient anti-fibrotic therapies that will increase patient survival, improve recovery, decrease the degree of permanent disabilities, improve patient quality life and lower healthcare costs meeting both the clinical and socio-economic needs.